Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

Part of paid clinical trials in Temple, Texas.

Sponsor
Baylor Research Institute
Study ID
NCT07547878
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 84 Years
Healthy Volunteers
Not accepted

Interventions

  • Finerenone — DRUG
    10-40mg daily
  • Semaglutide — DRUG
    .25-1.0mg 1 time a week
  • Lotensin — DRUG
    10-40mg daily
  • Capoten — DRUG
    12.5-50mg 3 times a day
  • Enalapril — DRUG
    2.5-10mg daily
  • Monopril — DRUG
    10-40mg daily
  • Lisinopril — DRUG
    5-20mg daily
  • Univasc — DRUG
    3.75-15mg daily
  • Aceon — DRUG
    4-16mg daily
  • Accupril — DRUG
    10-40mg daily
  • Altace — DRUG
    1.25-5mg daily
  • Mavik — DRUG
    1-4mg daily
  • Edarbi — DRUG
    40-80mg daily
  • Atacand — DRUG
    8-32mg daily
  • Avapro — DRUG
    150-300mg daily
  • Cozaar — DRUG
    25-100mg daily
  • Benicar — DRUG
    20-40mg daily
  • Micardis — DRUG
    20-80mg daily
  • Diovan — DRUG
    80-320mg daily
  • Invokana — DRUG
    100mg daily
  • Farxiga — DRUG
    10mg daily
  • Jardiance — DRUG
    10mg daily
  • Ertugliflozin — DRUG
    5mg daily
  • Brenzavvy — DRUG
    20mg daily
  • Sotagliflozin — DRUG
    200-400mg daily

Study Details

The goal of this clinical trial is to learn if starting four kidney disease medicines quickly and together (a rapid treatment approach) is safe and works well in people with type 2 diabetes and chronic kidney disease. The main questions it aims to answer are: * Is it safe to start these medicines over a short period of time? * How often do kidney function changes or high potassium levels occur? * Does this approach lower protein in the urine (a sign of kidney damage)? * How many participants are able to stay on all four medicines over 6 months? Researchers will compare this approach to usual care, where medicines are started one at a time over several months. Participants will: Be assigned by chance to either this approach or usual care Start up to four approved kidney medicines over about 8 weeks (rapid treatment approach) or follow standard care Have regular clinic visits and lab tests to check kidney function and potassium levels Be followed for about 6 months

Key Dates

Start date
Apr 30, 2026
Status verified
Apr 2026
Primary completion
Mar 31, 2029
Completion
Mar 31, 2029

Study Design

Enrollment
64 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Interventional Group
    Subjects receive all four chronic kidney disease therapies (medications) at the same time.
  • Active Comparator: Control Group
    Subjects received standard of care

Primary Outcome Measure

On-study retention rate at 6 months [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Baylor Scott and White Medical Center- TempleTempleTexas76508
Shahzeb Khan, MD
[email protected]
469-326-2636
Shahzeb Khan, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Temple, TX

By condition
Chronic kidney diseaseType 2 diabetes
By specialty
NephrologyKidney diseaseEndocrinologyMetabolic healthWeight loss
By research site
Baylor Scott and White Medical Center- Temple· Temple, TX

Related Studies